norspan transdermaalne plaaster
mundipharma ges.m.b.h. - buprenorfiin - transdermaalne plaaster - 20mcg 1h 5tk; 20mcg 1h 4tk; 20mcg 1h 12tk; 20mcg 1h 2tk; 20mcg 1h 3tk; 20mcg 1h 1tk
norspan transdermaalne plaaster
mundipharma ges.m.b.h. - buprenorfiin - transdermaalne plaaster - 10mcg 1h 8tk; 10mcg 1h 12tk; 10mcg 1h 4tk; 10mcg 1h 10tk; 10mcg 1h 1tk; 10mcg 1h 2tk; 10mcg 1h 5tk
norspan transdermaalne plaaster
mundipharma ges.m.b.h. - buprenorfiin - transdermaalne plaaster - 5mcg 1h 3tk; 5mcg 1h 8tk; 5mcg 1h 10tk; 5mcg 1h 1tk; 5mcg 1h 4tk; 5mcg 1h 5tk; 5mcg 1h 12tk
matrifen transdermaalne plaaster
takeda pharma as - fentanüül - transdermaalne plaaster - 25mcg 1h 3tk; 25mcg 1h 4tk; 25mcg 1h 8tk; 25mcg 1h 5tk; 25mcg 1h 16tk; 25mcg 1h 1tk; 25mcg 1h 2tk; 25mcg 1h 20tk; 25mcg 1h 10tk
matrifen transdermaalne plaaster
takeda pharma as - fentanüül - transdermaalne plaaster - 100mcg 1h 10tk; 100mcg 1h 8tk; 100mcg 1h 20tk; 100mcg 1h 4tk; 100mcg 1h 3tk; 100mcg 1h 5tk; 100mcg 1h 1tk; 100mcg 1h 16tk
matrifen transdermaalne plaaster
takeda pharma as - fentanüül - transdermaalne plaaster - 12mcg 1h 10tk; 12mcg 1h 5tk; 12mcg 1h 16tk; 12mcg 1h 8tk; 12mcg 1h 2tk; 12mcg 1h 1tk; 12mcg 1h 20tk; 12mcg 1h 4tk
matrifen transdermaalne plaaster
takeda pharma as - fentanüül - transdermaalne plaaster - 75mcg 1h 20tk; 75mcg 1h 2tk; 75mcg 1h 4tk; 75mcg 1h 10tk; 75mcg 1h 5tk; 75mcg 1h 1tk; 75mcg 1h 3tk; 75mcg 1h 8tk
matrifen transdermaalne plaaster
takeda pharma as - fentanüül - transdermaalne plaaster - 50mcg 1h 8tk; 50mcg 1h 4tk; 50mcg 1h 2tk; 50mcg 1h 3tk; 50mcg 1h 5tk; 50mcg 1h 10tk; 50mcg 1h 16tk
budesonide/formoterol teva pharma b.v.
teva pharma b.v. - budesonide, formoterol - astma - ravimid hingamisteede obstruktiivsete haiguste, - budesonide / formoterol teva pharma b. on näidustatud ainult 18-aastastel ja vanematel täiskasvanutel. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.